PMID- 25566624
OWN - NLM
STAT- MEDLINE
DCOM- 20150516
LR  - 20181202
IS  - 1003-5370 (Print)
IS  - 1003-5370 (Linking)
VI  - 34
IP  - 11
DP  - 2014 Nov
TI  - [Effect of activating blood circulation or activating blood circulation and 
      detoxication on platelet activation, inflammation, and coagulation status in 
      acute myocardial infarction rats].
PG  - 1329-34
AB  - OBJECTIVE: To observe the effect of activating blood circulation drugs or 
      activating blood circulation and detoxication drugs on indices of platelet 
      activation, inflammation, and coagulation status correlated with blood-stasis and 
      toxin in acute myocardial infarction rats. METHODS: Totally 100 male SD rats were 
      randomly divided into the sham-operation group, the model group, the activating 
      blood circulation group, the activating blood circulation and detoxication group, 
      and the metoprolol group, 20 in each group. Rats in the activating blood 
      circulation group were administered with Xiongshao Capsule at the daily dose of 
      0.39 g/kg. Rats in the activating blood circulation and detoxication group were 
      administered with Xiongshao Capsule (at the daily dose of 0.39 g/kg) and 
      Huanglian Capsule (at the daily dose of 0.135 g/kg). Rats in the metoprolol group 
      received metoprolol at the daily dose of 2.25 mg/kg. And rats in the rest two 
      groups were administered with normal saline. All medication lasted for 3 
      successive weeks. After the last administration, the rat model of acute 
      myocardial infarction was prepared by ligation of left anterior descending 
      artery. No ligation was given to rats in the sham-operation group. Animals were 
      sacrificed 24 h after modeling. Tumor necrosis factor-alpha (TNF-alpha), 
      beta-thromboglobulin (beta-TG), platelet alpha granule membrane protein-140 (GMP-140), 11 
      dehydro-thromboxane B2 (11-DH-TXB2), fibrinopeptide A (FPA), antithrombin III 
      (AT-III), and D-dimer (DD) were detected by ELISA. The mRNA expression of TNF-alpha 
      was tested by RT-PCR. RESULTS: Platelet activation parameters were significantly 
      increased in the model group, when compared with the sham-operation group (P < 
      0.01). Compared with the model group, all indices (except GMP-140 in the 
      metoprolol group) obviously decreased in each medicated group (P < 0.01, P < 
      0.05). Besides, beta-TG and 11-DH-TXB2 were superior in the activating blood 
      circulation and detoxication group to that of the metoprolol group (P < 0.05). 
      But 11-DH-TXB2 was also obviously superior in the activating blood circulation 
      and detoxication group to that of the activating blood circulation group (P < 
      0.05). Compared with the sham-operation group, an obviously hypercoagulable state 
      was obviously shown in the AMI model group, with significantly increased FPA and 
      DD (P < 0.05 or 0.01) and significantly decreased AT III (P < 0.01). Compared 
      with the model group, the FPA level significantly decreased in each medicated 
      group (P < 0.01), and the AT III level significantly increased in the activating 
      blood circulation group and the activating blood circulation and detoxication 
      group (both P < 0.01). The level of DD obviously decreased in the activating 
      blood circulation and detoxication group (P < 0.01). Besides, the 3 indices were 
      superior in the activating blood circulation and detoxication group to those of 
      the metoprolol group (P < 0.05). Compared with the sham-operation group, the 
      serum TNF-alpha level and myocardial TNF-alpha mRNA expression were significantly 
      increased in the model group (P < 0.05, P < 0.01). Compared with the model group, 
      not only the serum TNF-alpha level was significantly decreased, but also the TNF-alpha 
      gene expression in the myocardial tissue was improved in the activating blood 
      circulation and detoxication group (P < 0.01). CONCLUSION: Combined use of 
      activating blood circulation and detoxication drugs could play an effective role 
      in treatment of coronary heart disease by fighting against platelet activation, 
      improving the hypercoagulable state, and inhibiting inflammation, which was 
      significantly better than using activating blood circulation and removing stasis 
      drugs alone.
FAU - Ma, Xiao-Juan
AU  - Ma XJ
AD  - Xiyuan Hospital, Chinese Academy of Medical Sciences, Beijing, China
FAU - Guo, Chun-Yu
AU  - Guo CY
FAU - Yin, Hui-Jun
AU  - Yin HJ
FAU - Liu, Yue
AU  - Liu Y
FAU - Shi, Da-Zhuo
AU  - Shi DZ
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Zhong Xi Yi Jie He Za Zhi
JT  - Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese 
      journal of integrated traditional and Western medicine
JID - 9211576
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (fibrin fragment D)
RN  - 0 (huanglian)
RN  - 0 (xiongshao)
SB  - IM
MH  - Animals
MH  - Drugs, Chinese Herbal/pharmacology
MH  - Fibrin Fibrinogen Degradation Products
MH  - Inflammation/metabolism
MH  - Male
MH  - Medicine, Chinese Traditional
MH  - Myocardial Infarction/*physiopathology
MH  - Myocardium/metabolism
MH  - Platelet Activation/drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 2015/01/09 06:00
MHDA- 2015/05/20 06:00
CRDT- 2015/01/09 06:00
PHST- 2015/01/09 06:00 [entrez]
PHST- 2015/01/09 06:00 [pubmed]
PHST- 2015/05/20 06:00 [medline]
PST - ppublish
SO  - Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014 Nov;34(11):1329-34.